Target intelligence / Profile preview

Cyclic GMP-AMP synthase (mouse) (cGAS)

Target
cGAS
Molecular classification
Enzyme, DNA sensor, Innate immune receptor (Pattern recognition receptor), Nucleotidyltransferase family
01

Overview

Cyclic GMP-AMP synthase (cGAS) is a cytosolic enzyme and DNA sensor in mouse and other mammals that detects double-stranded DNA (dsDNA) in the cytoplasm, typically of pathogenic origin or released from damaged host cells[1][6][7]. Upon binding dsDNA, cGAS catalyzes the synthesis of the cyclic dinucleotide 2′,3′-cyclic GMP-AMP (cGAMP) from ATP and GTP[2][7]. cGAMP then functions as a second messenger, binding to the adaptor protein STING and triggering downstream signaling cascades that ultimately lead to the production of type I interferons and proinflammatory cytokines[6]. The cGAS–STING pathway constitutes a major component of the innate immune system’s response to intracellular DNA, playing key roles in antiviral defense, tumor immunity, and, if dysregulated, the development of autoinflammatory and autoimmune diseases[5]. Murine cGAS shares conserved structure and function with human cGAS, with well-characterized DNA binding and catalytic sites facilitating its activation and signal transduction[1][3][7].

Other names
cGAMP synthasecGASCgas (gene symbol)Cyclic GMP–AMP synthase (murine)Mouse cGAS
02

Mechanism of action

Inhibitors: block DNA binding, enzyme activity, or downstream cGAMP production[2]. Agonists: promote activation of cGAS to induce interferon production for antitumor/antiviral effects[2].

03

Biological functions

Cytosolic DNA sensingInnate immune response activationProduction of type I interferonsSignal transductionAntiviral defense
04

Disease associations

InfectionInflammationAutoimmune diseaseCancer (via tumor immunity and immunosurveillance)
05

Safety considerations

Aberrant activation can cause unwanted inflammation and autoimmunity[5].Inhibition may suppress host defense against infections and tumors[5].
06

Interacting drugs

No approved drugs directly targeting cGAS are currently on the market; experimental small molecule inhibitors/modulators exist in preclinical or early research settings[2].
07

Biomarkers

No clinically established biomarkers specific for cGAS activity, but type I interferon or cGAMP levels may be considered as research markerscGAS expression itself may serve as a research biomarker[5]

Beyond the preview

Go deeper on Cyclic GMP-AMP synthase (mouse) (cGAS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic GMP-AMP synthase (mouse) (cGAS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call